TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures .
/PRNewswire/ TargED Biopharmaceuticals ("TargED"), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today.
- Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures - Funds
DGAP-News: Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.